Literature DB >> 27586180

Pituitary Apoplexy After Initial Leuprolide Injection.

Andrew J Fabiano1, Saby George2.   

Abstract

BACKGROUND: Pituitary apoplexy is a rare complication of the initial administration of leuprolide acetate. CASE DESCRIPTION: We present the case of a 63-year-old man who experienced headache, blurred vision, and loss of consciousness after initial leuprolide treatment for prostate carcinoma. Neuroimaging showed pituitary hemorrhage.
CONCLUSIONS: Clinicians should be aware of this rare but known complication of leuprolide injection so that prompt diagnosis and treatment initiation are performed in patients with leuprolide-associated pituitary apoplexy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leuprolide acetate; Pituitary apoplexy; Pituitary hemorrhage; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27586180     DOI: 10.1016/j.wneu.2016.08.091

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.

Authors:  Georges Tanios; Nicolas Andrews Mungo; Aaysha Kapila; Kailash Bajaj
Journal:  BMJ Case Rep       Date:  2017-07-14

Review 2.  GnRH agonist-associated pituitary apoplexy: a case series and review of the literature.

Authors:  Francisco J Guarda; Xiaoling Yu; Philip J Saylor; Lisa B Nachtigall; Naila Shiraliyeva; Melanie S Haines; Michael Bradbury
Journal:  Pituitary       Date:  2021-04-09       Impact factor: 4.107

3.  Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment.

Authors:  Mariana Barbosa; Sílvia Paredes; Maria João Machado; Rui Almeida; Olinda Marques
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-06-04

4.  Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.

Authors:  Rishi Raj; Ghada Elshimy; Aasems Jacob; P V Akhila Arya; Dileep C Unnikrishnan; Riccardo Correa; Zin W Myint
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-22       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.